Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vatiquinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 7/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CDC25B | P30305 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | SI | P14410 | 2/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vatiquinone SCHEMBL14639355 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL13835534 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL2587312 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL6126503 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| Vatiquinone SCHEMBL502414 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL24736747 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL13836177 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL2591895 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| Vatiquinone SCHEMBL502413 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B | |
| SCHEMBL30132923 | 1.00 | ALOX15 (1.00) | ALOX15MAOBPTPN2PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727532-A1 | METHODS FOR INCREASING VATIQUINONE PLASMA EXPOSURE WITH FOOD | PTC Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| WO-2025085275-A1 | SYNTHESIS, FABRICATION AND USE OF NANOPARTICLES WITH ATOMIC VACANCIES FOR MITOCHONDRIAL THERAPIES | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2025059302-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT AND MODULATION OF ACUTE AND CHRONIC SYMPTOMS OF MITOCHONDRIAL DISEASE AND DYSFUNCTION | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-03-20 | — | — | WO | claimed |
| WO-2025040686-A1 | QUINONES FOR USE IN THE TREATMENT OF RED BLOOD CELL ENZYMOPATHIES | Abliva Ab (SE) | 2025-02-27 | — | — | WO | claimed |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | RIBONOVA INC. (US) | 2025-01-02 | — | — | US | claimed |
| WO-2024259130-A1 | METHODS FOR INCREASING VATIQUINONE PLASMA EXPOSURE WITH FOOD | PTC THERAPEUTICS, INC. (US) | 2024-12-19 | — | — | WO | claimed |
| WO-2024199144-A1 | NOVEL REAGENT FOR MITIGATING LNP TOXICITY | SHANGHAI MOYIN THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | WO | claimed |
| EP-4397369-A2 | METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION | Ribonova Inc. (US) | 2024-07-10 | — | — | EP | claimed |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2024-01-18 | — | — | US | claimed |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | RENEO PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | claimed |
| US-20220204469-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2022-06-30 | — | — | US | claimed |
| EP-4014050-A1 | HIGH-SENSITIVITY IMMUNOASSAY FOR THE DETECTION OF FRATAXIN IN BIOFLUIDS | Voyager Therapeutics, Inc. (US) | 2022-06-22 | — | — | EP | claimed |
| US-20220133648-A1 | TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES | PTC THERAPEUTICS, INC. | 2022-05-05 | — | — | US | claimed |
| US-11312697-B2 | Process for the production of alpha-tocotrienol and derivatives | PTC THERAPEUTICS, INC. (US) | 2022-04-26 | — | — | US | claimed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220033903-A1 | GENETIC MARKERS ASSOCIATED WITH ASD AND OTHER CHILDHOOD DEVELOPMENTAL DELAY DISORDERS | LINEAGEN, INC. | 2022-02-03 | — | — | US | claimed |
| US-20190002428-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2019-01-03 | — | — | US | claimed |
| EP-2963006-B1 | COMPOSITION CONTAINING ALPHA-TOCOTRIENOL QUINONE,AND INTERMEDIATES THEREOF | BIOELECTRON TECH CORP (US) | 2018-10-17 | — | — | EP | claimed |
| US-20170037023-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | PTC THERAPEUTICS, INC. | 2017-02-09 | — | — | US | claimed |
| EP-2963006-A1 | COMPOSITION CONTAINING ALPHA-TOCOTRIENOL QUINONE,AND INTERMEDIATES THEREOF | Edison Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204469-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | ALOX15 81/4885MAOB 2757/4885PTPN2 4381/4885 |
| US-20170037023-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | ALOX15 81/4885MAOB 2757/4885PTPN2 4381/4885 |
| US-20220133648-A1 | TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES | MTCH2, NDUFA3, NDUFS3 | ALOX15 407/4885MAOB 1710/4885PTPN2 4695/4885 |
| US-20190002428-A1 | PROCESS FOR THE PRODUCTION OF ALPHA-TOCOTRIENOL AND DERIVATIVES | TTPA, LCAT, PCTP | ALOX15 81/4885MAOB 2757/4885PTPN2 4381/4885 |
| US-20230233570-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | ALOX15 796/4885MAOB 2993/4885PTPN2 1361/4885 |
| US-11312697-B2 | Process for the production of alpha-tocotrienol and derivatives | TTPA, LCAT, PCTP | ALOX15 81/4885MAOB 2757/4885PTPN2 4381/4885 |
| US-20250000817-A1 | Methods of Treating Mitochondrial Dysfunction | SLC25A20, NDUFAB1, HAGH | ALOX15 1288/4885MAOB 1111/4885PTPN2 4234/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | ALOX15 1469/4885MAOB 3624/4885PTPN2 4401/4885 |
| US-20240016809-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF DISEASE | PPARG, PPARD, PPARA | ALOX15 796/4885MAOB 2993/4885PTPN2 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.